Background/Aims: Intensive haemodialysis (HD) sometimes causes hypophosphataemia, but phosphate-containing dialysate is not readily available. We examined the effectiveness of extemporaneously producing a phosphate-rich dialysate for use in HD. Methods: Incremental volumes of Fleet® were added to acid concentrate and predicted to deliver dialysate phosphate concentrations of 0.19–1.1 mmol/l, following mixture with ultrapure water and base concentrate by the HD machine. Results: The achieved concentrations were close to predicted values (p = 0.77) and remained stable throughout an 8-hour ‘treatment’ time (p = 0.99). The dialysate phosphate concentration had a linear relationship with the Fleet® volume added, defined by the regression equation y = 172.79 x – 1.47 (R2 = 0.99, r = 0.99, p = 0.003). The dialysate pH, calcium, magnesium and bicarbonate concentrations did not change over the study period (p = 0.28–0.99). Microscopic analysis under polarised light showed no evidence of crystal formation. Conclusion: The study validates a simple, reliable and cost-effective protocol for phosphate supplementation in conventional and extended HD.

Keywords:
Haemodialysis, Dialysate, Phosphate, Calcium, Hypophosphataemia
1.
Agar JW, Somerville CA, Simmonds RE, Boddington JM: Nocturnal dialysis – the 1st Australian experience. Hemodial Int 2003;7:73–104.
2.
Molnar J, Szabo D, Mandi Y, Mucsi I, Fischer J, Varga A, König S, Motohashi N: Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 1998;18:3033–3038.
3.
Albalate M, Gruss E, Hernandez J, Carmelo C: Hypophosphatemia in dialysis units. Nefrologia 2003;23:252–256.
4.
Chow MT, Lin HJ, Mitra EA, Singh S, Lee E, Leehey DJ, Ing TS: Hemodialysis-induced hypophosphatemia in a normophosphatemic patient dialyzed for ethylene glycol poisoning: treatment with phosphorus-enriched hemodialysis. Artif Organs 1998;22:905–907.
5.
Dorval M, Pichette V, Cardinal J, Geadah D, Ouimet D, Leblanc M: The use of an ethanol- and phosphate-enriched dialysate to maintain stable serum ethanol levels during haemodialysis for methanol intoxication. Nephrol Dial Transplant 1999;14:1774–1777.
6.
Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS: In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010;363:2287–2300.
7.
Boelens PA, Norwood W, Kjellstrand C, Brown DM: Hypophosphatemia with muscle weakness due to antacids and hemodialysis. Am J Dis Child 1970;120:350–353.
8.
Brunelli SM, Goldfarb S: Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007;18:1999–2003.
9.
Fajardo L, Campistrus N, Rios P, Gomez T: Evolution of serum phosphate in long intermittent hemodialysis. Kidney Int Suppl 2003;85:S66–S68.
10.
Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG: Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis 2004;43:85–89.
11.
Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998;53:1399–1404.
12.
Chebrolu SB, Chaudhury S, Bidani A, Kjellstrand CM, Ing TS: Phosphorus-enriched hemodialysis for the treatment of hypophosphatemia in a patient with severe lithium poisoning. Hemodial Int 2004;8:95.
13.
Khan MA, Yu AW, Cheng YL, Di Silvestro JA, Yung CY, Ing TS: Preparation of a phosphorus-enriched hemodialysate using an ‘acid concentrate’ solution and a sodium bicarbonate powder. Am J Nephrol 1998;18:172–173.
14.
Leehey DJ, Ing TS: Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis 1997;29:288–290.
15.
Troyanov S, Geadah D, Ghannoum M, Cardinal J, Leblanc M: Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy. Intensive Care Med 2004;30:1662–1665.
16.
Santiago MJ, Lopez-Herce J, Urbano J, Bellon JM, Castillo JD, Carrillo A: Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children. Kidney Int 2008;75:312–316.
17.
Santiago MJ, López-Herce J, Muñoz R, del Castillo J, Urbano J, Solana MJ, Botrán M: Stability of continuous renal replacement therapy solutions after phosphate addition: an experimental study. Ther Apher Dial 2011;15:75–80.
18.
Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G: Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011;55:39–45.
19.
Gatchalian RA, Popli A, Ejaz AA, Leehey DJ, Kjellstrand CM, Ing TS: Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate. Am J Kidney Dis 2000;36:1262–1266.
20.
Kerr PG, Polkinghorne KR, McDonald SP: Home hemodialysis in Australia: current perspective. Hemodial Int 2008;12:S6–S10.
21.
Pierides AM, Ellis HA, Ward MK, Aljama P, Dewar J, Kerr DN: The need and use of a phosphate-enriched dialysate during regular hemodialysis. Trans Am Soc Artif Intern Organs 1977;23:376–384.
22.
Kaye M, Vasilevsky M, Barber E: Correction of hypophosphatemia in patients on hemodialysis using a calcium-free dialysate with added phosphate. Clin Nephrol 1991;35:130–133.
23.
Wong JC, McDougal AR, Tofan M, Aulakh J, Pineault M, Chessex P: Doubling calcium and phosphate concentrations in neonatal parenteral nutrition solutions using monobasic potassium phosphate. J Am Coll Nutr 2006;25:70–77.
24.
Zabaneh RI, Bhatt DM, Yu AW, Tiwari P, Lai CI, Leehey DJ, Ing TS: Use of a phosphorus-enriched dialysate in a hypercatabolic renal failure patient receiving intensive hemodialysis therapy. Nephron 1996;72:696–698.
25.
Su WS, Lekas P, Carlisle EJ, Cowin R, Bellamy J, Margetts PJ, Brimble KS, Clase CM, Gangji AS: Management of hypophosphatemia in nocturnal hemodialysis with phosphate-containing enema: a technical study. Hemodial Int 2011;15:219–225.
26.
Yavorskyy A, Hernandez-Santana A, McCarthy G, McMahon G: Detection of calcium phosphate crystals in the joint fluid of patients with osteoarthritis – analytical approaches and challenges. Analyst 2008;133:302–318.
27.
Lumbreras B, Pascual E, Frasquet J, González-Salinas J, Rodríguez E, Hernández-Aguado I: Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005;64:612–615.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.